No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TXG240517P55000
- 16.20
- 0.000.00%
15min DelayClose May 3 15:58 ET
0.00High0.00Low
16.20Open16.20Pre Close0 Volume0 Open Interest55.00Strike Price0.00Turnover0.00%IV0.07%PremiumMay 17, 2024Expiry Date27.52Intrinsic Value100Multiplier13DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Express News | 10X Genomics Inc : Stephens Cuts Target Price to $45 From $62
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), 10x Genomics (TXG) and LivaNova (LIVN)
10x Genomics First Quarter 2024 Earnings: In Line With Expectations
Insider Moves Spark Speculation: 10X Genomics Executives Rethink Stock Sale Strategies
UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating
10x Genomics (TXG) has an average rating of outperform and price targets ranging from $26 to $62, according to analysts polled by Capital IQ. Price: 26.91, Change: -2.37, Percent Change: -8.09
10x Genomics Price Target Cut to $32.00/Share From $57.00 by TD Cowen
10x Genomics Price Target Cut to $32.00/Share From $57.00 by TD Cowen
Comments
Analysts predict 10x Genomics will reach cashflow breakeven before depleting its cash reserves. The company appears well-positioned to fund its growth, with options to raise more capital through share issuance or debt.
We're Not Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn 1
James Wilbur's share sale prompts doubts about insiders’ view of stock's worth. No insider buying in past year may hint at uncertainty in company's future, despite high insider ownership suggesting management's awareness of shareholders' interests.
$10x Genomics(TXG.US$ why the jump up today in price action?
Read more